On 3 May, the European Comission published the "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".

The guideline is related to proteins and polypeptides, their derivatives and products of which they are components and addresses the specific documentation requirements on the biological, chemical and pharmaceutical quality of IMPs containing biological / biotechnology derived substances in cases where no 'simplified IMPD' is submitted.

Amongst others, the document includes in its first part necessary information on manufacturing, characterisation, reference standards and stability of active substances as well as investigational medicinal products currently tested. The second part are four appendices with the focus on

• Facilities and Equipement
• Adventitious agents safety evaluation
• Excipients
• Solvents for reconstitution and diluents

The third part of the guideline covers a non-exhaustive list of  typically 'substantial' amendments.

Please see the complete "Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials".

Author
Axel H. Schroeder
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)

Related GMP News
23/05/2013	EU: New Q&A Document on Clinical Trials
23/05/2013	FDA Two new Q&As published for Investigational Drugs
23/05/2013	QP Template for IMPs manufactured in third Countries
06/03/2013	ICH publishes New Draft Guideline on Genotoxic Impurities
14/02/2013	New EU Template for QP Declaration (IMPs)